Novelion Therapeutics (NVLN) & Its Peers Critical Comparison
Novelion Therapeutics (NASDAQ: NVLN) is one of 187 public companies in the “Biotechnology & Medical Research” industry, but how does it compare to its competitors? We will compare Novelion Therapeutics to similar companies based on the strength of its risk, dividends, profitability, institutional ownership, valuation, earnings and analyst recommendations.
Risk and Volatility
Novelion Therapeutics has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500. Comparatively, Novelion Therapeutics’ competitors have a beta of 1.55, indicating that their average stock price is 55% more volatile than the S&P 500.
This table compares Novelion Therapeutics and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Novelion Therapeutics Competitors||-4,558.30%||-563.91%||-43.32%|
Valuation and Earnings
This table compares Novelion Therapeutics and its competitors gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Novelion Therapeutics||$13.57 million||-$52.87 million||-0.50|
|Novelion Therapeutics Competitors||$217.29 million||-$39.39 million||-65.05|
Novelion Therapeutics’ competitors have higher revenue and earnings than Novelion Therapeutics. Novelion Therapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Insider & Institutional Ownership
75.6% of Novelion Therapeutics shares are held by institutional investors. Comparatively, 48.2% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 14.1% of Novelion Therapeutics shares are held by company insiders. Comparatively, 14.5% of shares of all “Biotechnology & Medical Research” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
This is a breakdown of current ratings and price targets for Novelion Therapeutics and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Novelion Therapeutics Competitors||542||2454||6687||128||2.65|
Novelion Therapeutics presently has a consensus price target of $8.00, suggesting a potential upside of 128.57%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 14.56%. Given Novelion Therapeutics’ higher possible upside, research analysts clearly believe Novelion Therapeutics is more favorable than its competitors.
Novelion Therapeutics competitors beat Novelion Therapeutics on 7 of the 12 factors compared.
Novelion Therapeutics Company Profile
Novelion Therapeutics Inc, formerly QLT Inc., is a Canada-based biopharmaceutical company. The Company is engaged in development of new standards of care for individuals living with rare diseases. The Company is focused on advancing its portfolio of rare disease therapies by investing in science and clinical development. The Company holds a portfolio of products through its subsidiary, Aegerion Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. The Company’s portfolio of products include MYALEPT and JUXTAPID. The Company is also developing zuretinol acetate for the treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes.
Receive News & Ratings for Novelion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novelion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.